Momenta Pharmaceuticals Inc., of Cambridge, Mass., said it priced an underwritten public offering of 17.39 million shares of its common stock at $11.50 each for total gross proceeds of approximately $200 million. The offering underwriter has been granted a 30-day option to purchase up to an additional 2.6 million shares.